Compare DraftKings Inc (DKNG) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DraftKings Inc vs Illumina, Inc. — how do they compare? DraftKings Inc trades at $25.24 (market cap $12.58B), while Illumina, Inc. trades at $193.06 (market cap $29.12B). The key difference: Illumina, Inc. is far larger — about 2.3× DraftKings Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, DraftKings Inc nearer its low. Which is the better fit depends on your goals.
| DKNG | ILMN | |
|---|---|---|
Market Cap | $12.58B | $29.12B |
Sector | Consumer Cyclical | Health |
52-Week High | $48.23 | $205.10 |
52-Week Low | $20.72 | $91.00 |
Enterprise Value | $13.51B | $30.48B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
